A practical learning and reflection space on the challenges of injection-moulded plastic part development and the decisions that matter before committing to production tooling.
Thermoplastic elastomers (TPE, TPU, TPV, PEBA) introduce variables that no rigid prototype can reproduce: functional demoulding, processed Shore hardness, overmoulding adhesion and sterilisation compatibility. Validating with substitute materials transfers that risk to the production mould.
Equiplast 2026 and the international plastics trade show circuit confirm the same direction: process validation, traceability, energy efficiency and real data before the production mould.
Validating engineering plastic parts with ABS, SLA or other substitute materials can hide shrinkage, tolerance and mechanical-behaviour errors. This article explains why production material must enter the prototype phase.
In medical programs, evidence from substitute-material prototypes is not enough. This article explains how final-material injection at prototype phase reduces technical and regulatory risk before series launch.
Medical devicesRegistered materialInjection moulding
Geometric checks alone do not prevent production rejects. If final material and real injection conditions are not validated early, risk is transferred to production tooling, where corrections become slower and more expensive.
When each component passes tolerance checks but the final assembly fails, the issue is rarely in CAD alone. It is usually a late validation problem. This article explains why and how to avoid carrying that risk into production tooling.